Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
University of Bristol and Bristol Urological Institute, Bristol, United Kingdom. Electronic address: marcus.drake@bui.ac.uk.
Marcus J
MJ
Drake
Alliance Urology Specialists, Greensboro, NC.
Scott
S
MacDiarmid
Pavlov First Saint Petersburg State Medical University, Saint Petersburg, Russia.
Salman
S
Al-Shukri
Humber River Hospital, University of Toronto, Toronto, ON, Canada.
Jack
J
Barkin
Karolinska University Hospital, Huddinge, Stockholm, Sweden.
Aino
A
Fianu-Jonasson
Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
Sender
S
Herschorn
Astellas Pharma Europe Ltd, Chertsey, Surrey, United Kingdom.
Moses
M
Huang
Astellas Pharma Global Development, Leiden, The Netherlands.
Matthias
M
Stoelzel
Astellas Pharma Europe Ltd, Chertsey, Surrey, United Kingdom.
Emad
E
Siddiqui
D000083:Acetanilides / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002404:Catheterization; D015331:Cohort Studies; D005260:Female; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D018727:Muscarinic Antagonists / Q000627:therapeutic use; D011469:Prostatic Diseases / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D012115:Residual Volume; D012306:Risk; D000069464:Solifenacin Succinate / Q000008:administration & dosage*; D013844:Thiazoles / Q000008:administration & dosage*; D016896:Treatment Outcome; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*; D016055:Urinary Retention / Q000188:drug therapy* / Q000517:prevention & control*; D014563:Urodynamics; D064804:Urological Agents / Q000008:administration & dosage
D000083:Acetanilides; D018727:Muscarinic Antagonists; D013844:Thiazoles; D064804:Urological Agents; D000069464:Solifenacin Succinate; C520025:mirabegron